Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

NVAX

+ Watchlist+ Portfolio

Novavax, Inc.

Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$7.96
52-Week Range
$6.20 – $13.39
Market Cap
$1.31B
P/E (TTM)
—
EPS (TTM)
-0.52
Dividend Yield
0.00%
Advanced Metrics
Price/Book
—
PEG Ratio
1.32
Return on Equity
—
Return on Assets
-4.22%
Gross Margin
5.30%
Operating Margin
-16.98%
Profit Margin
-18.64%
Current Ratio
2.15
Debt/Equity
—
Total Debt
$295.26M
Free Cash Flow
$11.76M
Revenue Growth
-3.00%
Earnings Growth
—
Enterprise Value
$986.37M

Market Snapshot

About

Novavax, Inc. is a biotechnology company that develops next-generation vaccines for serious infectious diseases. The company gained prominence with its protein-based COVID-19 vaccine (Nuvaxovid) and is advancing candidates for influenza, COVID-flu combination vaccines, and other respiratory diseases. Novavax uses proprietary recombinant nanoparticle technology and Matrix-M adjuvant to enhance immune response.